Tag: Elahere
FDA grants full approval to AbbVie’s ovarian cancer drug ELAHERE
AbbVie (NYSE: ABBV) has achieved a significant milestone in the fight against ovarian cancer with the U.S. Food and Drug Administration (FDA) granting full approval ... Read More
AbbVie to acquire ImmunoGen for $10.1bn to expand oncology portfolio
AbbVie Inc. and ImmunoGen Inc. have entered into a definitive agreement, marking a significant move in the pharmaceutical industry. AbbVie will acquire ImmunoGen, including its ... Read More
ImmunoGen to get nearly $175m financing from Pharmakon Advisors
ImmunoGen, a US-based biotechnology company, will receive a non-dilutive term loan financing facility for up to $175 million from entities managed by Pharmakon Advisors. The ... Read More